A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
NRG Oncology
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Cambridge University Hospitals NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
McGill University
Yale University
Auron Healthcare GmbH